Edgewise Therapeutics, Inc.
SEC CIK 1710072 · EWTX · last insider filing 2026-06-17
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Thompson Peter A. | Director | filed 2021 - 2026 |
| Morris Arlene | Director | filed 2024 - 2026 |
| Brege Laura | Director | filed 2021 - 2026 |
| Fox Jonathan C | Director | filed 2023 - 2026 |
| Edris Badreddin | Director | filed 2021 - 2026 |
| Martin Christopher Nathan | Director | filed 2025 - 2026 |
| Russell Alan J | Director · Chief Scientific Officer | filed 2021 - 2025 |
| Koch Kevin | Director · President and CEO | filed 2021 - 2025 |
| Root Jonathan D | Director | filed 2021 - 2025 |
| Orbimed Advisors LLC | Director | filed 2021 - 2025 |
| Orbimed Capital GP VI LLC | Director | filed 2021 - 2025 |
| Orbimed Genesis GP LLC | Director | filed 2021 - 2025 |
| Harrison Kenneth Ph.D. | Director | filed 2021 - 2021 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Donovan Joanne M. | CMO | filed 2021 - 2026 |
| Nofi Michael | Chief Financial Officer | filed 2025 - 2025 |
| Moore John R | General Counsel | filed 2021 - 2025 |
| Carruthers R Michael | Chief Financial Officer | filed 2021 - 2025 |
| Derakhshan Behrad | Chief Business Officer | filed 2021 - 2025 |
| Blaustein Robert | Chief Development Officer | filed 2025 - 2025 |
| Semigran Marc | Chief Development Officer | filed 2022 - 2024 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.